Every material Form 8-K Ocugen, Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ocugen reported third quarter 2026 results, with revenue rising to $1.951 million and net loss narrowing to $3.6 million from $20.1 million a year earlier. The narrower loss came mainly from a $16.6 million change in the fair value of a derivative liability, while operating loss widened slightly to $17.8 million, and cash and short-term investments totaled $84.6 million as of September 30, 2026.
Collaborative arrangement revenue was $1.951 million, compared with $1.752 million in the third quarter of 2025.
Total operating expenses were $19.7 million, up from $19.4 million, including $12.5 million in research and development.
Net loss per share was $(0.01), compared with $(0.07) a year earlier; the filing says cash is expected to fund operations into 2028.
Ocugen signed an exclusive OCU400 license for the Middle East and North Africa with Roots Pharmaceutical, with up to $4 million in upfront and initial development milestone payments and a 22% royalty on net sales.
Ocugen furnished an October 2026 investor presentation as Exhibit 99.1 under Regulation FD, which it will post on its website on October 15, 2026. The deck covers clinical programs for OCU400, OCU410ST and OCU410, and reiterates a target of three Biologics License Applications by 2028. The filing contains no reported quarterly financial results, guidance, or new financing, so it gives shareholders updated clinical timelines rather than changes to financial performance.
Company will post the presentation on its website on October 15, 2026.
OCU400 Phase 3 liMeliGhT trial has 140 patients enrolled; topline data expected 1H 2027 and BLA filing targeted for 2Q 2027.
Company targets three BLAs by 2028 across OCU400, OCU410ST and OCU410.
Presentation states OCU400 received provisional approval and priority designation from the Bahamas Regulatory Agency for an Early Access Program.
Ocugen signed an exclusive license agreement with Roots Pharmaceutical Company on October 13, 2026, for its OCU400 gene therapy for retinitis pigmentosa in certain Middle East and North Africa countries. Ocugen will receive up to $4 million in upfront and development payments, up to $255 million in sales milestones, and a 22% royalty on Roots' net sales, and will also supply the product under a separate agreement. On the same day, the board postponed the Special Meeting of Stockholders on the proposal to increase authorized common shares by 250,000,000 to December 22, 2026.
Up-front license fee and development milestones of up to $4 million in aggregate
Sales milestone payments of up to $255 million and a 22% royalty on net sales in the Territory
Special Meeting on the authorized share increase postponed to December 22, 2026; new record date is October 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ocugen, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →